KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amgen (AMGN) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for Amgen (AMGN) over the last 17 years, with Q4 2025 value amounting to $642.0 million.

  • Amgen's Capital Expenditures rose 7304.58% to $642.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.9 billion, marking a year-over-year increase of 6952.55%. This contributed to the annual value of $1.9 billion for FY2025, which is 6952.55% up from last year.
  • Latest data reveals that Amgen reported Capital Expenditures of $642.0 million as of Q4 2025, which was up 7304.58% from $436.0 million recorded in Q3 2025.
  • Amgen's Capital Expenditures' 5-year high stood at $642.0 million during Q4 2025, with a 5-year trough of $160.0 million in Q3 2022.
  • For the 5-year period, Amgen's Capital Expenditures averaged around $294.1 million, with its median value being $253.0 million (2023).
  • As far as peak fluctuations go, Amgen's Capital Expenditures plummeted by 3388.43% in 2022, and later skyrocketed by 8105.26% in 2023.
  • Amgen's Capital Expenditures (Quarter) stood at $287.0 million in 2021, then rose by 18.47% to $340.0 million in 2022, then decreased by 26.76% to $249.0 million in 2023, then skyrocketed by 49.0% to $371.0 million in 2024, then skyrocketed by 73.05% to $642.0 million in 2025.
  • Its last three reported values are $642.0 million in Q4 2025, $436.0 million for Q3 2025, and $369.0 million during Q2 2025.